Benefits of switching women schizophrenic patients to aripiprazole: A case study and brief review of the literature

Archives of Women's Mental Health

Volumn 13, Issue 5, 2010, Pages 443-447

  Kuloglu, Murat ^a   Ekinci, Okan ^b   Albayrak, Yakup ^b   Caykoylu, Ali ^b  

^a FIRAT UNIVERSITY   (Turkey)

^b ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Aripiprazole; Hyperprolactinemia; Schizophrenia; Switching

Indexed keywords

ARIPIPRAZOLE; PROLACTIN; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; AMENORRHEA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MONOTHERAPY; OLIGOMENORRHEA; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE ANTAGONISTS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPROLACTINEMIA; MIDDLE AGED; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RECURRENCE; SCHIZOPHRENIA;

EID: 78049375042     PISSN: 14341816     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00737-010-0150-x     Document Type: Article

References (32)

1. K Aihara J Shimada T Miwa, et al. 2004 The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release Brain Res 1003 9 17 1:CAS:528:DC%2BD2cXhvFaisL0%3D 10.1016/j.brainres.2003.09. 082 15019558 (Pubitemid 38317079)
2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders text rev, 4th edn. American Psychiatric Association Press, Washington, DC
3. I Anghelescu J Wolf 2004 Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report J Clin Psychiatry 65 1286 1287 10.4088/JCP.v65n0918f 15367061
4. KD Burris TF Molski C Xu, et al. 2002 Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors Pharmacol Exp Ther 302 381 389 1:CAS:528:DC%2BD38Xlt1SnsLY%3D 10.1124/jpet.102.033175 (Pubitemid 34680462)
5. MJ Byerly RN Marcus QV Tran, et al. 2009 Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study Schizophr Res 107 218 222 10.1016/j.schres.2008.09.019 19038534
6. DE Casey WH Carson AR Saha, et al. 2003 Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study Psychopharmacology (Berl) 166 391 399 1:CAS:528:DC%2BD3sXit12msb0%3D
7. CH Chen MC Huang ML Lu 2008 Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient Prog Neuropsychopharmacol Biol Psychiatry 32 893 894 1:CAS:528:DC%2BD1cXislaltLg%3D 10.1016/j.pnpbp.2007. 11.007 18082301 (Pubitemid 351320540)
8. PM Haddad A Wieck 2004 Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management Drugs 64 2291 2314 1:CAS:528:DC%2BD2cXpvVyrtrk%3D 10.2165/00003495-200464200-00003 15456328 (Pubitemid 39388605)
9. S Jordan V Koprivica R Chen, et al. 2002 The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor Eur J Pharmacol 441 137 140 1:CAS:528:DC%2BD38XksVSiurg%3D 10.1016/S0014-2999(02)01532-7 12063084 (Pubitemid 34626163)
10. SR Kay A Fiszbein LA Opler 1987 The Positive and Negative Syndrome Scale (PANSS) for schizophrenia Schizophr Bull 13 261 276 1:STN:280: DyaL2s3ptF2huw%3D%3D 3616518
11. CY Kim S Chung JN Lee, et al. 2009 A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder Int Clin Psychopharmacol 24 181 188 10.1097/YIC.0b013e32832c25d7 19451828
12. BJ Kinon BR Basson JA Gilmore, et al. 2000 Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine J Clin Psychiatry 61 833 840 1:CAS:528:DC%2BD3cXovVGgtbs%3D 10.4088/JCP.v61n1105 11105736
13. BH Lee YK Kim SH Park 2006 Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study Prog Neuropsychopharmacol Biol Psychiatry 30 714 717 1:CAS:528:DC%2BD28XjvVGht74%3D 10.1016/j.pnpbp.2006.02.001 16571367
14. RA Lorenz B Weinstein 2007 Resolution of haloperidol-induced hyperprolactinemia with aripiprazole J Clin Psychopharmacol 27 524 525 10.1097/JCP.0b013e31814f4d5d 17873694 (Pubitemid 47415060)
15. ML Lu WW Shen CH Chen 2008 Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole Prog Neuropsychopharmacol Biol Psychiatry 32 1978 1981 1:CAS:528: DC%2BD1cXhsVeru77N 10.1016/j.pnpbp.2008.09.016 18848860
16. D Mamo A Graff R Mizrahi, et al. 2007 Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study Am J Psychiatry 164 1411 1417 10.1176/appi.ajp.2007.06091479 17728427 (Pubitemid 47461142)
17. SR Marder RD McQuade E Stock, et al. 2003 Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials Schizophr Res 61 123 136 10.1016/S0920-9964(03)00050-1 12729864 (Pubitemid 36513927)
18. A Mir K Shivakumar RJ Williamson, et al. 2008 Change in sexual dysfunction with aripiprazole: a switching or add-on study J Psychopharmacol 22 244 253 1:CAS:528:DC%2BD1cXovVelsLY%3D 10.1177/0269881107082901 18308789 (Pubitemid 351847447)
19. AL Montejo 2008 Prolactin awareness: an essential consideration for physical health in schizophrenia Eur Neuropsychopharmacol 18 108 114 10.1016/j.euroneuro.2008.02.004 (Pubitemid 351381354)
20. JE Overall DR Gorham 1962 The brief psychiatric rating scale Psychol Rep 10 799 812 10.2466/PR0.10.3.799-812
21. CU Pae A Serretti A Chiesa, et al. 2009 Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study Eur Neuropsychopharmacol 19 562 570 1:CAS:528:DC%2BD1MXnvVWnurs%3D 10.1016/j.euroneuro.2009.04.002 19442491
22. M Paulzen G Gründer 2007 Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole Int J Neuropsychopharmacol 10 149 151 1:CAS:528:DC%2BD2sXltlSguw%3D%3D 10.1017/S1461145706007115 16942633 (Pubitemid 46122764)
23. J Peuskens 2000 Switching approach in the management of schizophrenia patients Int Clin Psychopharmacol 15 15 19 10.1097/00004850-200015060-00005
24. SG Potkin AR Saha MJ Kujawa, et al. 2003 Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder Arch Gen Psychiatry 60 681 690 1:CAS:528:DC%2BD3sXmtVOjs7o%3D 10.1001/archpsyc.60.7.681 12860772 (Pubitemid 36818630)
25. M Raja 2007 Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole Int J Neuropsychopharmacol 10 107 110 1:CAS:528:DC%2BD2sXltlSgsQ%3D%3D 10.1017/S1461145706006523 16487453 (Pubitemid 46122757)
26. S Ramaswamy D Vijay M William, et al. 2004 Aripiprazole possibly worsens psychosis Int Clin Psychopharmacol 19 45 48 10.1097/00004850-200401000-00009 15101571 (Pubitemid 38114625)
27. G Remington P Chue E Stip, et al. 2005 The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 76 267 272 10.1016/j.schres.2005.01.009 15949658 (Pubitemid 40804772)
28. JC Shim JG Shin DL Kelly, et al. 2007 Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial Am J Psychiatry 164 1404 1410 10.1176/appi.ajp.2007.06071075 17728426 (Pubitemid 47461141)
29. A Szarfman JM Tonning JG Levine, et al. 2006 Atypical antipsychotics and pituitary tumors: a pharmacovigilance study Pharmacotherapy 26 748 758 1:CAS:528:DC%2BD28XmtFKhu78%3D 10.1592/phco.26.6.748 16716128 (Pubitemid 43807626)
30. R Wahl R Ostroff 2005 Reversal of symptomatic hyperprolactinemia by aripiprazole Am J Psychiatry 162 1542 1543 10.1176/appi.ajp.162.8.1542-a 16055781
31. PJ Weiden PF Buckley 2007 Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications J Clin Psychiatry 68 14 23 1:CAS:528:DC%2BD2sXos1Cgsrc%3D 10.4088/JCP.0607e14
32. J Wolf U Fiedler 2007 Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole J Clin Pharm Ther 32 197 198 1:STN:280:DC%2BD2s7otFOntw%3D%3D 10.1111/j.1365-2710.2007.00806.x 17381670 (Pubitemid 46449704)